The characteristics of selleck inhibitor North American travelers (NAM) and European travelers (EUR) were compared using chi-square test, t-test, and odds ratios calculation with 95% confidence intervals.

The study protocol was approved by the Research Office from the Medical School of the Universidad Nacional de San Antonio Abad del Cusco. During the study period, 6,798 international travelers were approached; 5,988 (88%) agreed to participate and completed the questionnaire. Information from 1,612 NAM and 3,590 EUR was retrieved from the database. Questionnaires excluded from the analysis (786 questionnaires) belonged mainly to travelers residing in developing countries in the Americas. The mean age of NAM was 38.1 years (SD 12.88); 52.2% (836 of 1,601) were females; 47.9% (767 of 1,601) were single; 88.4% (1,424 of 1,611) visited Cusco mainly for tourism; and 89.4% (1,437 of 1,607) traveled with companions. The mean age of EUR was 34.2 years (SD 10.41); 50.7% (1,808 of 3,566) were females; 53.2%

(1,897 of 3,567) were single; 92.2% (3,308 of 3,589) visited Cusco mainly for tourism; and 91.2% (3,258 of 3,572) traveled with companions. The demographic characteristics of both groups are compared in Table Talazoparib 1. NAM reported being ill during their stay in Cusco more frequently than EUR [58.5% (943 of 1,612) vs 42% (1,510 of 3,590), p < 0.01]. They also reported more than one illness more often [23.6% (380 of 1,612) vs 14.1% (505 of 3,590), respectively, p < 0.01]. Among those who admitted being ill in Cusco, NAM reported diarrhea less often [46.7% (440 of 943) vs 55.6% (839 of 1,510), p < 0.01] and AMS more frequently [52.8% (497 of 941) vs 35.2% (531 of 1,509), p < 0.01] than EUR. No significant differences were found regarding the prevalence of sun burns, isolated fever, upper respiratory tract symptoms, sexually transmitted diseases, and traffic accidents. There were

small differences between NAM and EUR regarding the reception of information on travel-related health Mirabegron issues [93.1% (1,494 of 1,604) vs 96.9% (3,454 of 3,566), p < 0.01] and the likelihood of consulting more than one source of information [51.5% (768 of 1,491) vs 56.9% (1,963 of 3,449), p < 0.01]. EUR received information from a health care professional more often [67.1% (2,318 of 3,453) vs 52% (776 of 1,491), p < 0.01]. Specifically, they received information from a travel medicine practitioner [45.8% (1,583 of 3,453) vs 37% (552 of 1,491), p < 0.01] or a general practice physician [28.2% (975 of 3,453) vs 19.5% (291 of 1,491), p < 0.01] more often. The sources of pre-travel health information are compared in Table 2. The frequency of vaccination was significantly lower among NAM [67.3% (1,079 of 1,603) vs 85.5% (3,053 of 3,570), p < 0.01] as was the mean number of vaccines received by each subject (1.97 SD 1.68 vs 2.63 SD 1.49; t-test 14.02, p < 0.01).